<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="several other cardiovascular as well as noncardiovascular therapeutic uses of" exact="propranolol" post="were discovered. Propranolol soon became a powerful tool for"/>
 <result pre="and pheochromocytoma. Owing to its action at multiple receptor sites," exact="propranolol" post="exerts several central and peripheral effects and is therefore"/>
 <result pre="reduction in postmyocardial mortality to control of anxiety in performers," exact="propranolol" post="plays an important role in a plethora of medical"/>
 <result pre="newer indications of this age-old drug are being discovered. Moreover," exact="propranolol" post="treatment has been found to be cost-effective when compared"/>
 <result pre="In this article, we attempt to recount the journey of" exact="propranolol" post="right from its inception to the present day. Keywords:"/>
 <result pre="the present day. Keywords: Anxiety beta-blocker myocardial infarction portal hypertension" exact="propranolol" post="I NTRODUCTION The invention of the beta-adrenergic receptor antagonist,"/>
 <result pre="led to the development of propranolol.[ 3 4 5] Until" exact="propranolol" post="was invented, the only drugs available to treat angina"/>
 <result pre="which were effective only partially. Soon, it was discovered that" exact="propranolol" post="is not only effective in the treatment of angina,"/>
 <result pre="2 6 7 8] Over the years, other applications of" exact="propranolol" post="in several noncardiovascular conditions including migraine, essential tremors, anxiety,"/>
 <result pre="conditions. In this article, we will review the journey of" exact="propranolol" post="from its inception to the present day. M ECHANISM"/>
 <result pre="beta-1 and beta-2 adrenergic receptors. By blocking the beta-adrenergic sites," exact="propranolol" post="inhibits sympathetic effects that act through these receptors.[ 11"/>
 <result pre="Two-dimensional (a) and three-dimensional (b) representation of molecular structure of" exact="propranolol" post="(C16H21NO2) Propranolol is highly lipophilic. Following oral administration, complete"/>
 <result pre="of its metabolites are excreted in urine. Plasma half-life of" exact="propranolol" post="is 3–6 h.[ 11 12] A long-acting preparation of"/>
 <result pre="propranolol is 3–6 h.[ 11 12] A long-acting preparation of" exact="propranolol" post="has also been developed with a half-life of 8–11"/>
 <result pre="HERAPEUTIC U SES OF P ROPRANOLOL The widespread use of" exact="propranolol" post="in cardiovascular diseases including ischemic heart disease, arrhythmias, and"/>
 <result pre="50 years. Here, we will also discuss the role of" exact="propranolol" post="in various noncardiovascular conditions with special emphasis on its"/>
 <result pre="commonly used class of drugs for managing cardiovascular diseases. Although" exact="propranolol" post="was first developed to manage angina pectoris, soon its"/>
 <result pre="= 3837), which was designed to evaluate whether administration of" exact="propranolol" post="postmyocardial infarction led to reduction in mortality. Results were"/>
 <result pre="was found to be acceptable. The results also showed that" exact="propranolol" post="has an antiarrhythmic effect which may, at least in"/>
 <result pre="positive results of this study led to widespread use of" exact="propranolol" post="for reduction in morbidity and mortality associated with myocardial"/>
 <result pre="15] Many new generation cardioselective beta-blockers are now available. Nevertheless," exact="propranolol" post="continues to be used in specific conditions. Propranolol has"/>
 <result pre="acute myocardial infarction. Propranolol, being cost-effective, can be preferred over" exact="carvedilol" post="for this indication.[ 16] Barton et al. assessed the"/>
 <result pre="Barton et al. assessed the efficacy and safety of high-dose" exact="propranolol" post="for the management of supraventricular tachyarrhythmias (SVTs) in infants"/>
 <result pre="through entire inpatient stay, and 87.7% of those discharged on" exact="propranolol" post="were recurrence-free at follow-up.[ 17] Several other studies also"/>
 <result pre="follow-up.[ 17] Several other studies also support the efficacy of" exact="propranolol" post="in treating SVT in infants.[ 18 19] Apart from"/>
 <result pre="in treating SVT in infants.[ 18 19] Apart from propranolol," exact="digoxin" post="has also been used to treat SVT in this"/>
 <result pre="this patient population. The evidence related to comparative efficacy/safety of" exact="propranolol" post="and digoxin has been conflicting. Bolin et al. conducted"/>
 <result pre="population. The evidence related to comparative efficacy/safety of propranolol and" exact="digoxin" post="has been conflicting. Bolin et al. conducted a large"/>
 <result pre="retrospective database study including 2657 neonates and found that while" exact="digoxin" post="and propranolol were the most commonly prescribed drugs for"/>
 <result pre="study including 2657 neonates and found that while digoxin and" exact="propranolol" post="were the most commonly prescribed drugs for SVT in"/>
 <result pre="commonly prescribed drugs for SVT in infants, the use of" exact="digoxin" post="decreased to 23% and propranolol increased to 77% of"/>
 <result pre="in infants, the use of digoxin decreased to 23% and" exact="propranolol" post="increased to 77% of all the antiarrhythmic medications prescribed"/>
 <result pre="2015. They also found that odds for mortality in the" exact="propranolol" post="arm were 0.32 times than that for the digoxin"/>
 <result pre="the propranolol arm were 0.32 times than that for the" exact="digoxin" post="arm (confidence interval [CI]: 0.17–0.59; P &amp;lt; 0.001). Moreover,"/>
 <result pre="[CI]: 0.17–0.59; P &amp;lt; 0.001). Moreover, hospital costs in the" exact="propranolol" post="group were significantly lesser than that in the digoxin"/>
 <result pre="the propranolol group were significantly lesser than that in the" exact="digoxin" post="group ( P = 0.003). Thus, it can be"/>
 <result pre="P = 0.003). Thus, it can be safely said that" exact="propranolol" post="is superior to digoxin in the management of SVT"/>
 <result pre="it can be safely said that propranolol is superior to" exact="digoxin" post="in the management of SVT in infants.[ 20] Furthermore,"/>
 <result pre="digoxin in the management of SVT in infants.[ 20] Furthermore," exact="propranolol" post="has also shown promising results in heart failure caused"/>
 <result pre="the exact mechanism of its antihypertensive effect is not known," exact="propranolol" post="is known to work through several mechanisms including peripheral"/>
 <result pre="and renin–angiotensin–aldosterone–sympathetic axis inhibition.[ 11] Further, the anxiolytic effect of" exact="propranolol" post="is also well known.[ 23] Based on all these"/>
 <result pre="also well known.[ 23] Based on all these factors, presently," exact="propranolol" post="is being considered for the treatment of resistant arterial"/>
 <result pre="27] Rabkin et al. accidentally found the therapeutic effect of" exact="propranolol" post="for migraine while they were studying its use in"/>
 <result pre="pectoris.[ 2] Since then, several studies have been conducted wherein" exact="propranolol" post="was found to be safe and effective in managing"/>
 <result pre="such studies (N = 2403) that assessed the effect of" exact="propranolol" post="on migraine headaches. Reduction in migraine activity was 44%"/>
 <result pre="and global patient reports were used to assess efficacy) for" exact="propranolol" post="and only 14% for placebo.[ 32] A Cochrane review"/>
 <result pre="Rossnagel evaluated 58 clinical trials assessing efficacy and safety of" exact="propranolol" post="compared to placebo and other drugs (including other beta-blockers,"/>
 <result pre="several other drugs) in adults with migraine. The results showed" exact="propranolol" post="to be more effective than placebo and as effective"/>
 <result pre="CI: −1.86–−0.07; divalproex: −1.28, 95% CI: −2.44–−0.27). Moreover, patients with" exact="topiramate" post="or propranolol also exhibited significantly reduced headache frequency compared"/>
 <result pre="divalproex: −1.28, 95% CI: −2.44–−0.27). Moreover, patients with topiramate or" exact="propranolol" post="also exhibited significantly reduced headache frequency compared to placebo"/>
 <result pre="−1.17, 95% CI: −1.98–−0.35; propranolol: −1.37, 95% CI: −2.49–−0.29). Further," exact="propranolol" post="was found to be safer and more tolerable when"/>
 <result pre="found to be safer and more tolerable when compared to" exact="topiramate" post="(propranolol vs. topiramate, all adverse events: odds ratio (OR):"/>
 <result pre="2.09, 95% CI: 1.11–4.52). Thus, considering all the parameters together," exact="propranolol" post="was the most beneficial treatment for migraine.[ 34] Propranolol"/>
 <result pre="for migraine treatment in children, of the several drugs studied," exact="propranolol" post="(propranolol vs. placebo: OR: 27.6, 95% CI: 6.58–115.77, P"/>
 <result pre="be effective.[ 35] In a randomized double-blind trial which compared" exact="propranolol" post="with sodium valproate for migraine prophylaxis in pediatric patients,"/>
 <result pre="In a randomized double-blind trial which compared propranolol with sodium" exact="valproate" post="for migraine prophylaxis in pediatric patients, while both drugs"/>
 <result pre="parameters, the reduction in baseline headache frequency was better with" exact="propranolol" post="( P = 0.044).[ 36] Hence, the beneficial effect"/>
 <result pre="( P = 0.044).[ 36] Hence, the beneficial effect of" exact="propranolol" post="in reducing headache frequency as seen in the network"/>
 <result pre="tremors start to affect activities of daily living. Propranolol and" exact="primidone" post="(anticonvulsant medication) are the first-line medications used, and propranolol"/>
 <result pre="and primidone (anticonvulsant medication) are the first-line medications used, and" exact="propranolol" post="is the only drug approved by the United States"/>
 <result pre="(FDA) for the treatment of essential tremors.[ 38] Efficacy of" exact="propranolol" post="in the treatment of essential tremors was first reported"/>
 <result pre="first reported in the early 1970s. The exact mechanism of" exact="propranolol" post="in essential tremors is not yet clear. However, it"/>
 <result pre="by the American Academy of Neurology published in 2011 recommend" exact="propranolol" post="and primidone as the first line of treatment (Level"/>
 <result pre="American Academy of Neurology published in 2011 recommend propranolol and" exact="primidone" post="as the first line of treatment (Level A, established"/>
 <result pre="been observed that about 50%–70% of the patients respond to" exact="propranolol" post="and 50% respond to primidone, when compared to placebo."/>
 <result pre="when compared to placebo. In addition, the dropout rate with" exact="propranolol" post="is &amp;lt;20% while that for primidone is 20%–30%.[ 38]"/>
 <result pre="the dropout rate with propranolol is &amp;lt;20% while that for" exact="primidone" post="is 20%–30%.[ 38] Thus, propranolol appears to have an"/>
 <result pre="is &amp;lt;20% while that for primidone is 20%–30%.[ 38] Thus," exact="propranolol" post="appears to have an advantage over primidone. Moreover, because"/>
 <result pre="an advantage over primidone. Moreover, because of limited availability of" exact="primidone" post="in India, propranolol turns out to be the first"/>
 <result pre="primidone. Moreover, because of limited availability of primidone in India," exact="propranolol" post="turns out to be the first choice.[ 40] Anxiety"/>
 <result pre="study, anxiety and depression scores were significantly lower in the" exact="propranolol" post="group ( P &amp;lt; 0.0001) when compared to the"/>
 <result pre="group.[ 42] Another study compared the efficacy and safety of" exact="propranolol" post="in patients receiving two different doses of propranolol (20"/>
 <result pre="safety of propranolol in patients receiving two different doses of" exact="propranolol" post="(20 mg and 40 mg) with those not receiving"/>
 <result pre="not receiving any anxiolytic medication. Anxiolysis scores improved significantly in" exact="propranolol" post="groups compared with control group ( P &amp;lt; 0.05).["/>
 <result pre="be changing in the recent years. Studies have shown that" exact="propranolol" post="can alter the way memories are stored in the"/>
 <result pre="This finding has led to a number of studies evaluating" exact="propranolol" post="in PTSD. A study by Vaiva et al. reported"/>
 <result pre="PTSD symptoms were reduced in patients with trauma exposure receiving" exact="propranolol" post="as compared to those not receiving the drug ("/>
 <result pre="( P = 0.037).[ 46] As per Mahabir et al.," exact="propranolol" post="not only alleviates the unpleasant memories related to a"/>
 <result pre="to prevent hemorrhage. Treatment options include nonselective beta-blockers such as" exact="propranolol" post="and endoscopic variceal ligation (EVL). The mechanism of action"/>
 <result pre="and endoscopic variceal ligation (EVL). The mechanism of action of" exact="propranolol" post="in portal hypertension is through both beta-1 and beta-2"/>
 <result pre="splanchnic vasoconstriction via unopposed alpha-adrenergic activity.[ 49 50] Studies comparing" exact="propranolol" post="and EVL have found both these measures to be"/>
 <result pre="is, therefore, considered as the first line of treatment. Moreover," exact="propranolol" post="is also believed to have a role in preventing"/>
 <result pre="for variceal bleeding in cirrhotic patients. This beneficial effect of" exact="propranolol" post="is due to reduction in bacterial translocation by increasing"/>
 <result pre="In patients with small varices but high risk of bleeding," exact="propranolol" post="is recommended as EVL may be technically difficult in"/>
 <result pre="with medium to large varices can be treated with either" exact="propranolol" post="or EVL.[ 50 51] The combination of propranolol and"/>
 <result pre="with either propranolol or EVL.[ 50 51] The combination of" exact="propranolol" post="and EVL is used in the prevention of recurrent"/>
 <result pre="a high native HVPG and a reduction in HVPG following" exact="propranolol" post="treatment, thus demonstrating that treatment with propranolol is also"/>
 <result pre="in HVPG following propranolol treatment, thus demonstrating that treatment with" exact="propranolol" post="is also effective in patients with advanced portal hypertension.["/>
 <result pre="recent study by Kim et al. compared the effectiveness of" exact="candesartan" post="and propranolol combination therapy with propranolol monotherapy in reducing"/>
 <result pre="by Kim et al. compared the effectiveness of candesartan and" exact="propranolol" post="combination therapy with propranolol monotherapy in reducing portal hypertension"/>
 <result pre="compared the effectiveness of candesartan and propranolol combination therapy with" exact="propranolol" post="monotherapy in reducing portal hypertension in patients with cirrhosis."/>
 <result pre="therapy and monotherapy ( P = 0.674). Therefore, addition of" exact="candesartan" post="to propranolol in treating patients with portal hypertension is"/>
 <result pre="monotherapy ( P = 0.674). Therefore, addition of candesartan to" exact="propranolol" post="in treating patients with portal hypertension is not recommended.["/>
 <result pre="hyperthyroidism. In addition to relieving the troublesome symptoms of hyperthyroidism," exact="propranolol" post="is known to have an additional advantage of decreasing"/>
 <result pre="Pretreatment with a combination of an alpha-adrenergic blocker such as" exact="phenoxybenzamine" post="and beta-blocker propranolol helps in preventing such complications.[ 61"/>
 <result pre="combination of an alpha-adrenergic blocker such as phenoxybenzamine and beta-blocker" exact="propranolol" post="helps in preventing such complications.[ 61 62] Recent advances"/>
 <result pre="62] Recent advances The first report of the use of" exact="propranolol" post="in infantile hemangioma was published in 2008.[ 63] Further"/>
 <result pre="hemangioma was published in 2008.[ 63] Further studies have reported" exact="propranolol" post="to be safe and effective for this indication.[ 64"/>
 <result pre="safe and effective for this indication.[ 64 65 66] Recently," exact="propranolol" post="has also shown promise in certain other conditions. A"/>
 <result pre="17) showed that in substance-dependent subjects, drug-related memory reactivation under" exact="propranolol" post="reduced craving.[ 67] In another study, propranolol was associated"/>
 <result pre="memory reactivation under propranolol reduced craving.[ 67] In another study," exact="propranolol" post="was associated with less cancer-related psychological distress in patients"/>
 <result pre="newly diagnosed with cancer.[ 68] Furthermore, potential benefits of perioperative" exact="propranolol" post="in decreasing perioperative tumor growth have been suggested.[ 69]"/>
 <result pre="can be managed conservatively without requiring discontinuation of medication. Further," exact="propranolol" post="has demonstrated safety for use in pediatric patients.[ 11"/>
 <result pre="70] S UMMARY AND F UTURE D IRECTIONS In summary," exact="propranolol" post="was first developed to treat cardiovascular diseases but soon"/>
 <result pre="patients for surgery in hyperthyroidism and pheochromocytoma. Beta-adrenergic blockade by" exact="propranolol" post="also helps in reversing the hemodynamic abnormalities in portal"/>
 <result pre="the FDA for the treatment of essential tremors. In addition," exact="propranolol" post="is cost-effective compared to other available treatment options. Although"/>
 <result pre="propranolol is cost-effective compared to other available treatment options. Although" exact="propranolol" post="has now been around for more than 50 years"/>
 <result pre="Stables DP Levin NW Suzman MM The prophylactic value of" exact="propranolol" post="in angina pectoris Am J Cardiol 1966 18 370"/>
 <result pre="300 1 6 Besterman EM Friedlander DH Clinical experiences with" exact="propranolol" post="Postgrad Med J 1965 41 526 35 5827672 7"/>
 <result pre="5827672 7 Prichard BN Gillam PM Treatment of hypertension with" exact="propranolol" post="Br Med J 1969 1 7 16 5761914 8"/>
 <result pre="from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf 12 Routledge PA Shand DG Clinical pharmacokinetics of" exact="propranolol" post="Clin Pharmacokinet 1979 4 73 90 378502 13 Nace"/>
 <result pre="Lichstein E Byington R Beta-blocker heart attack trial: Impact of" exact="propranolol" post="therapy on ventricular arrhythmias Prev Med 1985 14 346"/>
 <result pre="SO Miyake C Kim JJ Efficacy and safety of high-dose" exact="propranolol" post="for the management of infant supraventricular tachyarrhythmias J Pediatr"/>
 <result pre="Valdes SO Miyake CY Decker JA et al. Efficacy of" exact="digoxin" post="in comparison with propranolol for treatment of infant supraventricular"/>
 <result pre="Decker JA et al. Efficacy of digoxin in comparison with" exact="propranolol" post="for treatment of infant supraventricular tachycardia: Analysis of a"/>
 <result pre="multicenter, randomized controlled trial comparing the efficacy and safety of" exact="digoxin" post="versus propranolol for prophylaxis of supraventricular tachycardia in infants"/>
 <result pre="controlled trial comparing the efficacy and safety of digoxin versus" exact="propranolol" post="for prophylaxis of supraventricular tachycardia in infants Circ Arrhythm"/>
 <result pre="Bolin EH Lang SM Tang X Collins RT Propranolol versus" exact="digoxin" post="in the neonate for supraventricular tachycardia (from the pediatric"/>
 <result pre="Weeraratne C Galappatthy P Rajapakse S et al. Addition of" exact="propranolol" post="in resistant arterial hypertension treatment (APROPRIATE study): Study protocol"/>
 <result pre="S Kudrow L Stevens J Shapiro DB Long-term study of" exact="propranolol" post="in the treatment of migraine Headache 1982 22 268"/>
 <result pre="71 7174304 30 Rosen JA Observations on the efficacy of" exact="propranolol" post="for the prophylaxis of migraine Ann Neurol 1983 13"/>
 <result pre="CD002761 36 Bidabadi E Mashouf M A randomized trial of" exact="propranolol" post="versus sodium valproate for the prophylaxis of migraine in"/>
 <result pre="E Mashouf M A randomized trial of propranolol versus sodium" exact="valproate" post="for the prophylaxis of migraine in pediatric patients Paediatr"/>
 <result pre="4 8679756 43 Khadke VV Khadke SV Khare A Oral" exact="propranolol" post="– Efficacy and comparison of two doses for peri-operative"/>
 <result pre="B Lestavel P Brunet A et al. Immediate treatment with" exact="propranolol" post="decreases posttraumatic stress disorder two months after trauma Biol"/>
 <result pre="BC et al. Equal efficacy of endoscopic variceal ligation and" exact="propranolol" post="in preventing variceal bleeding in patients with noncirrhotic portal"/>
 <result pre="Na JH Kim HS Kim HA et al. Effects of" exact="candesartan" post="and propranolol combination therapy versus propranolol monotherapy in reducing"/>
 <result pre="Kim HS Kim HA et al. Effects of candesartan and" exact="propranolol" post="combination therapy versus propranolol monotherapy in reducing portal hypertension"/>
 <result pre="et al. Effects of candesartan and propranolol combination therapy versus" exact="propranolol" post="monotherapy in reducing portal hypertension Clin Mol Hepatol 2014"/>
 <result pre="62 Mihai R Sadler GP Bridge H Adrenergic blockade with" exact="phenoxybenzamine" post="and propranolol in a cohort of 60 patients undergoing"/>
 <result pre="R Sadler GP Bridge H Adrenergic blockade with phenoxybenzamine and" exact="propranolol" post="in a cohort of 60 patients undergoing surgery for"/>
 <result pre="Posiunas G et al. A randomized, controlled trial of oral" exact="propranolol" post="in infantile hemangioma N Engl J Med 2015 372"/>
 <result pre="J Prey S Lebbé G et al. Safety of oral" exact="propranolol" post="for the treatment of infantile hemangioma: A Systematic review"/>
 <result pre="Brown TG Brunet A et al. Reactivating addiction-related memories under" exact="propranolol" post="to reduce craving: A pilot randomized controlled trial J"/>
 <result pre="TJ Choi CH Lee JW et al. Perioperative administration of" exact="propranolol" post="to women undergoing ovarian cancer surgery: A pilot study"/>
</results>
